Gene therapy is entering a new phase of innovation, with adeno-associated virus (AAV)-based treatments showing great promise for genetic disorders. Yet, immunogenicity risks remain a major hurdle in clinical development.
Cerba Research’s Roundtable report brings together leading experts to explore cutting-edge bioanalytical strategies, regulatory considerations, and the future of AAV therapy. This in-depth report examines the latest advancements in mitigating immunogenicity risks and enhancing therapeutic efficacy through innovative bioanalytical approaches.
Developing AAV-based therapies requires close collaboration between developers, laboratory service providers, and regulatory bodies. The report captures key discussions from the roundtable, including efforts to standardize pre-screening assays, refine dose optimization, and advance companion diagnostics (CDx) for safer, more effective treatments. Featuring insights from top scientists and industry leaders, it offers valuable takeaways for researchers, biotech companies, and regulatory professionals.
Stay ahead in gene therapy innovation. Download the full Citeline & Cerba Roundtable Report today for expert perspectives on overcoming immunogenicity challenges, aligning with regulatory expectations, and shaping the future of AAV-based treatments.
